Da	te:	2021/8/25			
		_Runde Jiang			
Ma	nuscript Ti	tle:Combination	of oncolytic adenovirus ZD	55 harboring TRAIL-IETD-MnSOD and cytokine-induced	<u>killer</u>
	ls against lu				
Ma	nuscript nu	ımber (if known)	:		
relator	ated to the rties whose transparend ationship/a	content of your interests may be cy and does not rectivity/interest,	manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current	
	nuscript on			· · · · · · · · · · · · · · · · · · ·	
to me	the epidem dication, ev	iology of hyperto ven if that medic ow, report all sup	ension, you should declare ation is not mentioned in t	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensiv he manuscript. d in this manuscript without time limit. For all other ite	e
			Name all entities with	Specifications/Comments	
			whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial	planning of the work	
1	manuscript provision of medical wri processing	for the present (e.g., funding, f study materials, iting, article charges, etc.) nit for this item.	_X_None		
			Time frame: past	36 months	
2		ontracts from if not indicated above).	XNone		
3	Royalties or	rlicenses	XNone		
	0 111	r	.		
4	Consulting	tees	XNone		

5	Payment or honoraria for	XNone		
	lectures, presentations, speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
_	0			
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
0	Participation on a Data	V N		
9	Safety Monitoring Board or	XNone		
	Advisory Board			
10	Leadership or fiduciary role	X None		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	X None		
12	materials, drugs, medical	X None		
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Ple	ase summarize the above co	onflict of interest in the fo	llowing box:	
	None			
Ple	Please place an "X" next to the following statement to indicate your agreement:			

Da	te:	2021/8/25			
		_ Zhixiong Zha			
Ma	anuscript Ti	tle:Combination	of oncolytic adenovirus ZD	55 harboring TRAIL-IETD-MnSOD and cytokine-induced	killer
	ls against lu				
Ma	anuscript nu	ımber (if known)	:		
rel pa to rel	ated to the rties whose transparend ationship/a	content of your interests may be cy and does not inctivity/interest, questions apply	manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so. ps/activities/interests as they relate to the current	
to me	the epidem edication, ev item #1 bel	iology of hyperto ven if that medic ow, report all su	ension, you should declare ation is not mentioned in t	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other iter	ve .
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial	planning of the work	
1	manuscript provision of medical wri processing	for the present (e.g., funding, f study materials, iting, article charges, etc.) hit for this item.	_X_None		
2	Cuanta	antro etc for our	Time frame: past	36 months	
Z		ontracts from if not indicated above).	XNone		
3	Royalties or	rlicenses	XNone		
4	Consulting	fees	XNone		

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNoneXNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone
Ple	ease summarize the above co	onflict of interest in the following box:

Da	te:2	2021/8/25			
		Xinghai Liao			•
Ma	anuscript Tit	le:Combination	of oncolytic adenovirus ZD	55 harboring TRAIL-IETD-MnSOD and cytokine-induce	<u>d killer</u>
	ls against lu				
Ma	anuscript nu	ımber (if known)	·		
rel pa to rel	ated to the rties whose transparenc ationship/a	content of your interests may be and does not octivity/interest, questions apply	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript. Disclosure represents a commitment of the manuscript. If you are in doubt about whether to list a so.	
to me	the epidem edication, ev item #1 belo	iology of hyperto ven if that medic ow, report all su	ension, you should declare ation is not mentioned in t	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertens the manuscript. d in this manuscript without time limit. For all other it	ive
			,		
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial	planning of the work	
1	manuscript provision of medical wri processing o	for the present (e.g., funding, study materials, ting, article charges, etc.) hit for this item.	_X_None		
			Time frame: past	36 months	
2		ontracts from if not indicated bove).	XNone		
3	Royalties or	licenses	XNone		
4	Consulting f	ees	XNone		

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNoneXNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone
Ple	ease summarize the above co	onflict of interest in the following box:

Da	te:	2021/8/25			
		_Liangjuan Hua			
Ma	anuscript Ti	tle:Combination	of oncolytic adenovirus ZD	55 harboring TRAIL-IETD-MnSOD and cytokine-induced	<u> killer</u>
	ls against lu				
Ma	anuscript nu	umber (if known)	:		
rel pa to rel	ated to the rties whose transparend ationship/a	content of your interests may be cy and does not ectivity/interest, questions apply	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current	
to me	the epidem edication, evi item #1 bel	iology of hyperto ven if that medic ow, report all su	ension, you should declare ation is not mentioned in t	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other iter	е
			Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			needed) Time frame: Since the initial	nlanning of the work	
1	All support	for the present		planning of the work	
•	manuscript provision of medical wri processing	(e.g., funding, f study materials,	_X_None		
			Time frame: past	36 months	
2		ontracts from if not indicated above).	XNone		
3	Royalties or	rlicenses	XNone		
4	Consulting	fees	XNone		

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNoneXNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone
Ple	ease summarize the above co	onflict of interest in the following box:

Da	te:2	2021/8/25			
		_Yilang Liao			
Ma	anuscript Tit	le:Combination	of oncolytic adenovirus ZD	55 harboring TRAIL-IETD-MnSOD and cytokine-induced	killer
	lls against lu				
Ma	anuscript nu	ımber (if known)	:		
rel pa to rel	ated to the rties whose transparend ationship/a	content of your interests may be and does not octivity/interest, questions apply	manuscript. "Related" mea e affected by the content on necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so. ps/activities/interests as they relate to the current	
to me	the epidem edication, ev item #1 belo	iology of hyperto ven if that medic ow, report all su	ension, you should declare ation is not mentioned in t	defined broadly. For example, if your manuscript pertai all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other ite	re
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial	nlanning of the work	
1	All support	for the present		planning of the work	
	manuscript provision of medical wri processing of	(e.g., funding, study materials,	_X_None		
2		ontracts from if not indicated bove).	Time frame: pastXNone	36 months	
3	Royalties or	licenses	XNone		
4	Consulting f	ees	X None		

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNoneXNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone
Ple	ease summarize the above co	onflict of interest in the following box:

Da	te:	2021/8/25			
		Weiyi Deng			
Ma	anuscript Ti	tle:Combination	of oncolytic adenovirus ZD	55 harboring TRAIL-IETD-MnSOD and cytokine-induced	l killer
	ls against l				
Ma	anuscript n	umber (if known)	:		
rel pa to rel	ated to the rties whose transparen ationship/a	content of your interests may be cy and does not activity/interest, questions apply	manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so. ps/activities/interests as they relate to the current	
to me	the epidem edication, e item #1 bel	niology of hyperto ven if that medic ow, report all su	ension, you should declare ation is not mentioned in t	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertension he manuscript. d in this manuscript without time limit. For all other ito	ve
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial	planning of the work	
1	manuscript provision o medical wr processing	for the present (e.g., funding, f study materials, iting, article charges, etc.) nit for this item.	_X_None		
			Time frame: past	36 months	
2		ontracts from (if not indicated above).	XNone		
3	Royalties o	r licenses	XNone		
4	Consulting	fees	XNone		

6	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNoneXNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone
13	Other financial or non- financial interests	XNone
Ple	ease summarize the above co	onflict of interest in the following box: